Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LT-02 for maintenance of remission in ulcerative colitis
NCT02280629Phase 3Completed
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Oct 2014
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of phosphatidylcholine (LT-02) in ulcerative colitis (UC) (3 arms), sponsored by Dr. Falk Pharma GmbH. Primary endpoint: Percentage of patients who are relapse-free and are not a treatment failure at 48 weeks. Started Oct 2014; status: completed.
02
Drugs
phosphatidylcholine (LT-02)
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02280629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02280629.